Literature DB >> 3266441

The effect of age upon the affinity of microsomal mono-oxygenase enzymes for substrate in human liver.

H A Wynne1, E Mutch, O F James, P Wright, M D Rawlins, K W Woodhouse.   

Abstract

Although the clearance of many oxidized drugs falls with age, a corresponding fall in the maximal activities of drug metabolizing enzymes has not been noted. The possibility of a fall in enzyme affinity for substrate with age, which could account for the observed changes, has not previously been investigated in human liver. We have studied the kinetics of the microsomal mono-oxygenase 7-ethoxycoumarin-O-de-ethylase in 17 human liver biopsy specimens. No correlation was observed between age and microsomal protein recovery, maximal enzyme activity or apparent enzyme affinity. Since microsomal mono-oxygenase activities and affinities appear not to change in human liver, other factors such as a fall in liver volume or blood flow must be responsible for the decline in clearance of many oxidized drugs which occurs with ageing.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3266441     DOI: 10.1093/ageing/17.6.401

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  13 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Predicting and preventing adverse drug reactions in the very old.

Authors:  Louis Merle; Marie-Laure Laroche; Thierry Dantoine; Jean-Pierre Charmes
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly.

Authors:  K W Woodhouse; H A Wynne
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 5.  Age-related changes in the gastrointestinal system. Effects on drug therapy.

Authors:  F L Iber; P A Murphy; E S Connor
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 6.  Liver function and phase I drug metabolism in the elderly: a paradox.

Authors:  D L Schmucker
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Authors:  Gezim Lahu; Andreas Hünnemeyer; Edgar Diletti; Martin Elmlinger; Peter Ruth; Karl Zech; Nigel McCracken; Axel Facius
Journal:  Clin Pharmacokinet       Date:  2010-09       Impact factor: 6.447

Review 8.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 9.  Age-related changes in hepatic function. Implications for drug therapy.

Authors:  K Woodhouse; H A Wynne
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

10.  The influence of age, liver size and enantiomer concentrations on warfarin requirements.

Authors:  H Wynne; L Cope; P Kelly; T Whittingham; C Edwards; F Kamali
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.